Stress-Responsive Gene FK506-Binding Protein 51 Mediates Alcohol-Induced Liver Injury Through the Hippo Pathway and Chemokine (C-X-C Motif) Ligand 1 Signaling

Hepatology. 2021 Sep;74(3):1234-1250. doi: 10.1002/hep.31800. Epub 2021 Aug 30.

Abstract

Background and aims: Chronic alcohol drinking is a major risk factor for alcohol-associated liver disease (ALD). FK506-binding protein 51 (FKBP5), a cochaperone protein, is involved in many key regulatory pathways. It is known to be involved in stress-related disorders, but there are no reports regarding its role in ALD. This present study aimed to examine the molecular mechanism of FKBP5 in ALD.

Approach and results: We found a significant increase in hepatic FKBP5 transcripts and protein expression in patients with ALD and mice fed with chronic-plus-single binge ethanol. Loss of Fkbp5 in mice protected against alcohol-induced hepatic steatosis and inflammation. Transcriptomic analysis revealed a significant reduction of Transcriptional enhancer factor TEF-1 (TEA) domain transcription factor 1 (Tead1) and chemokine (C-X-C motif) ligand 1 (Cxcl1) mRNA in ethanol-fed Fkbp5-/- mice. Ethanol-induced Fkbp5 expression was secondary to down-regulation of methylation level at its 5' untranslated promoter region. The increase in Fkbp5 expression led to induction in transcription factor TEAD1 through Hippo signaling pathway. Fkbp5 can interact with yes-associated protein (YAP) upstream kinase, mammalian Ste20-like kinase 1 (MST1), affecting its ability to phosphorylate YAP and the inhibitory effect of hepatic YAP phosphorylation by ethanol leading to YAP nuclear translocation and TEAD1 activation. Activation of TEAD1 led to increased expression of its target, CXCL1, a chemokine-mediated neutrophil recruitment, causing hepatic inflammation and neutrophil infiltration in our mouse model.

Conclusions: We identified an FKBP5-YAP-TEAD1-CXCL1 axis in the pathogenesis of ALD. Loss of FKBP5 ameliorates alcohol-induced liver injury through the Hippo pathway and CXCL1 signaling, suggesting its potential role as a target for the treatment of ALD.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Central Nervous System Depressants / pharmacology*
  • Chemokine CXCL1 / metabolism*
  • DNA Methylation
  • Ethanol / pharmacology*
  • Gene Expression Profiling
  • Hippo Signaling Pathway / genetics*
  • Humans
  • Inflammation
  • Liver Diseases, Alcoholic / genetics*
  • Liver Diseases, Alcoholic / metabolism
  • Liver Diseases, Alcoholic / pathology
  • Mice
  • Mice, Knockout
  • Neutrophil Infiltration / genetics
  • Promoter Regions, Genetic
  • Protein Serine-Threonine Kinases / metabolism
  • RNA, Messenger / metabolism
  • Signal Transduction
  • TEA Domain Transcription Factors
  • Tacrolimus Binding Proteins / genetics*
  • Tacrolimus Binding Proteins / metabolism
  • YAP-Signaling Proteins / metabolism

Substances

  • Central Nervous System Depressants
  • Chemokine CXCL1
  • Cxcl1 protein, mouse
  • RNA, Messenger
  • TEA Domain Transcription Factors
  • Tead1 protein, mouse
  • YAP-Signaling Proteins
  • Yap1 protein, mouse
  • Ethanol
  • Stk4 protein, mouse
  • Protein Serine-Threonine Kinases
  • Tacrolimus Binding Proteins
  • tacrolimus binding protein 5